Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Hanmi Pharmaceutical Co. Ltd
Hanmi Pharmaceutical Co. Ltd
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Graphs and graph data science in drug discovery
Life sciences data expert Dr Alexander Jarasch discusses what work being done at the Institut de Recherches Servier can teach us about using modern data technologies for early...
The (r)evolution of biocatalysis in API synthesis
Explore Farmhispania Group’s enzyme toolbox to develop cost-effective, green-by-design synthetic routes for the cGMP production of your small-molecule NCEs
From batch to continuous chemistry to continuous processing
The main challenge in many flow reactors lies in achieving a smooth and continuous flow within microchannels. Dec Group focuses on effectively transporting solid materials and...
PCI Pharma Services commences installation of sterile fill-finish and lyophilisation line
The Bedford, NH site will advance PCI's manufacturing capabilities with twin lyophilisers and a large-scale isolator filling line, making this the third sterile fill-finish...
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Manufacturing
GEA secures first-of-a-kind pharma order from Hanmi Pharmaceutical
Hanmi chose GEA as key vendor for a new plant under construction in South Korea
Research & Development
Janssen and Hanmi agree to develop a novel clinical-stage biologic to treat diabetes and obesity
Commercialisation of oxyntomodulin-based therapy will bolster Janssen's metabolism portfolio
Regulatory
AZ enters agreement with Hanmi and Amneal in US Nexium patent litigation
AZ says this removes need for a trial and avoids ‘considerable’ costs
Subscribe now